Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer.

被引：0
|
作者：
Cotte, Alexia [1 ]
Beniey, Michele [1 ]
Haque, Takrima [2 ]
Bechir, Nelly [2 ]
Hubert, Audrey [1 ]
Diallo, Korotoum W. [1 ]
Tran-Thanh, Danh [2 ]
Hassan, Saima N. [1 ]
机构：
[1] Univ Montreal, Ctr Rech Univ Montreal CRCHUM, Montreal, PQ H3C 3J7, Canada
[2] Ctr Rech Univ Montreal CRCHUM, Montreal, PQ, Canada
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1066
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Judy Garber on PARP inhibitors for triple-negative breast cancer
    Garber, Judy
    ONCOLOGY-NEW YORK, 2017, 31 (11): : 814 - +
  • [32] Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
    Loibl, Sibylle
    O'Shaughnessy, Joyce
    Untch, Michael
    Sikov, William M.
    Rugo, Hope S.
    McKee, Mark D.
    Huober, Jens
    Golshan, Mehra
    von Minckwitz, Gunter
    Maag, David
    Sullivan, Danielle
    Wolmark, Norman
    McIntyre, Kristi
    Lorenzo, Jose J. Ponce
    Metzger Filho, Otto
    Rastogi, Priya
    Symmans, W. Fraser
    Liu, Xuan
    Geyer, Charles E., Jr.
    LANCET ONCOLOGY, 2018, 19 (04): : 497 - 509
  • [33] Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer
    Liang, Hongyan
    Tan, Antoinette R.
    IDRUGS, 2010, 13 (09) : 646 - 656
  • [34] Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer
    Gong, Rong
    Ma, ZhongYe
    He, LinHao
    Jiang, ShiLong
    Cao, DongSheng
    Cheng, Yan
    CHEMICO-BIOLOGICAL INTERACTIONS, 2023, 382
  • [35] Synergistic chemosensitivity of triple-negative breast cancer cell lines to a PARP inhibitor, cisplatin and gemcitabine
    Hastak, Kedar
    Alli, Elizabeth
    Ford, James
    CANCER RESEARCH, 2009, 69
  • [36] PRMT5 inhibitor synergizes with PARP inhibitors in triple-negative breast cancer cells
    Suresh, Samyuktha
    McPherson, Lisa A.
    Ford, James M.
    CANCER RESEARCH, 2024, 84 (06)
  • [37] PLK1 inhibition overcomes PARP inhibitor resistance in triple-negative breast cancer
    Siraj, Abdul K.
    Poyil, Pratheesh Kumar
    Padmaja, Divya
    Parvathareddy, Sandeep Kumar
    Alobaisi, Khadija
    Begum, Rafia
    Almalik, Osama
    Al-Dayel, Fouad
    Al-Kuraya, Khawla S.
    CANCER RESEARCH, 2024, 84 (06)
  • [38] Preclinical efficacy of dasatinib in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer xenograft model
    Sun, Y.
    Lin, X.
    Carlson, Jh
    De, P.
    Dey, N.
    Williams, C.
    Leyland-Jones, B.
    CANCER RESEARCH, 2017, 77
  • [39] MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells
    Zeng, Xiaoqi
    Jiang, Shanshan
    Ruan, Simin
    Guo, Zhaoze
    Guo, Jingyun
    Liu, Minfeng
    Ye, Changsheng
    Dong, Jianyu
    MOLECULAR MEDICINE REPORTS, 2021, 24 (02)
  • [40] In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab-paclitaxel on triple-negative and luminal A breast cancer cells
    Topcul, Mehmet
    Cetin, Idil
    Turan, Suna Ozbas
    Ozar, Melek Ozlem Kolusayin
    ONCOLOGY REPORTS, 2018, 40 (01) : 527 - 535
12345